CLINICAL TRIALS
We currently have trials available for both persons with AD and for those who are unaffected but want to contribute to AD research. If you are interested in participating in any of the studies below or would simply like to be on a list for future studies which may arise, please contact Casandra Conover, Clinical Trials Coordinator at 916-734-6750. Clinical trial visits, of the most part, are held on Fridays and last 15 minutes for a screening to 6 hours for imaging studies.
Visit the ADEAR web site for a comprehensive description of these and other clinical trials. Study Name Design/ Requirements Eligibility Criteria Statin Study: Evaluates the safety and efficacy of simvastatin to slow the progression of AD. Closed: Not recruiting 18 months. Labs. Psychological tests. 6-7 clinical visits. Simvastatin. Age 50 or older. Mild to moderate AD . Not taking a statin. No known heart disease. Closed: Not recruiting Homocysteine Study: Reducing homocysteine to slow cognitive decline in AD Closed: Not recruiting 18 months Labs Psychological tests. 7-8 clinic visits MRI ECG Vitamin B Age 55 or older The first trial is open to persons with and without AD – couples are ideal Closed: Not recruiting DHA Can Omeg-3 fatty acids (DHA) slow the progression of Alzheimer's Disease. 18 Months Regular Clinic visits Neuropsychological tests Age >50. Mild to moderate Alzheimer's Disease Fluent in English or Spanish A friend or relative who can accompany the vounteer to all clinic visits ADNI How brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Closed: Not recruiting Magnetic Resonance Imaging (MRI) Positron Emission Tomography (PET) Lumbar Puncture (LP) Age 50-90. MCI A study partner. Able to undergo neuroimaging. Closed: Not recruiting APOE Study: The effect of APOE genotype on CSF cortisol concentrations in person with AD, nondemented older persons, and normal young and middle-aged persons will be determined Closed: Not recruiting Spinal fluid cortisol levels obtained through lumbar puncture Very brief study ~ 2 weeks` Age 18-90 Non smoking for 6 months AD and cognitively normal patients Closed: Not recruiting Huperzine A: assess the tolerability and effectiveness of Huperzine A in improving cognitive function in AD Closed: Not recruiting 24 weeks Clinic visits Psychological tests Labs Persons with AD. Not taking cholinesterase inhibitors Closed: Not recruiting Elan AAB-001 The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD) Closed Not recruiting   Diagnosis of probable AD Age from 50 to 85 years Magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD Fluency in English Stable doses of medications Closed Not recruiting A number of elements are administered each visit and may consist of any of the following: Informed Consent: This is a legal document that protects you. It describes who is doing the research study and what will be done if you choose to participate. Medical History Physical Examination Depression and psychiatric evaluation Laboratory tests EKG MRI Neurology Exam Cognitive assessment Physical assessment of cranial nerves, vision, hearing, and speech Tests for coordination and motor function Evaluation of movement disorders, reflexes, posture and gait Neuropsychological Evaluation Tests for Memory, Language, Visuo-spatial and Constructional Abilities, Executive Function and Attention
CENTER CONTACTS FOR RESEARCH SUPPORT Principal Investigator: Charles DeCarli, M.D. Telephone: (916) 734-6280 email: charles.decarli@ucdmc.ucdavis.edu Research Coordinators: For Martinez and Oakland: Carole Bibeau, R.N., M.S., Clinical Nurse & Research Coordinator-(925) 372-2485 email: cabibeau@ucdavis.edu Katharine Vieira RN, Clinical Nurse & Research Coordinator email: kevieira@ucdavis.edu For Sacramento and San Joaquin: Esther Lara, M.S.W., Research Coordinator (Se habla Español) (916) 734-5496 email: ellara@ucdavis.edu